Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/207483MICRONEEDLE ARRAY DELIVERY OF ADENOVIRUS VECTORED VACCINES WITH AND WITHOUT ADJUVANTS
WO 14.10.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/US2021/026364 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FALO, Louis, Jr.
Provided herein are microneedle array devices for delivery of recombinant adenovirus particles, methods of making the devices, and used for the devices. The microneedle array devices are storage-stable at 4ºC, retaining adenovirus infectivity for at least one month.
2.WO/2021/206105EXTRACELLULAR VESICLE SECRETION INHIBITOR FOR INHIBITING EXTRACELLULAR VESICLE SECRETION, AND USE OF THE SAME
WO 14.10.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2021/014693 Applicant THEORIA SCIENCE INC. Inventor OCHIYA Takahiro
Provided are a novel secretion inhibitor and a secretion inhibiting method relating to the secretion of an extracellular vesicle from a cell. This extracellular vesicle secretion inhibitor is characterized by containing an agent that blocks the serine synthesis pathway. Said cell is, for instance, a cancer cell such as a colon cancer cell, a lung cancer cell, a melanoma cell, a breast cancer cell, a pancreatic cancer cell, or a multiple myeloma cell.
3.WO/2021/205462MODIFIED GENOMES AND USE THEREOF
WO 14.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/IL2021/050412 Applicant SYNVACCINE LTD. Inventor TULLER, Tamir
Modified genomes of an organism comprising at least one coding sequence comprising at least one mutation, wherein the mutation generates an underrepresented sequence that is underrepresented in the unmodified genome of the organism are provided. Organism and cells comprising the modified genomes of the invention, pharmaceutical compositions comprising the organisms and cells of the invention, as well as methods of making the modified genomes are also provided.
4.WO/2021/207082METHOD FOR TREATING IMPLANTABLE DEVICE INFECTIONS
WO 14.10.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2021/025794 Applicant ADAPTIVE PHAGE THERAPEUTICS, INC. Inventor BASU, Subhendu
The invention relates to the field of phage therapy and is particularly directed at providing a phage-based composition and method for treating or preventing infections associated with implantable devices. The composition may be directly administered to the infected location of the device, optionally as a single dose, and/or by other modes of administrations, and may potentially avoid any requirement for replacing the implantable device.
5.20210315950ELIMINATION OF COLONIC BACTERIAL DRIVING LETHAL INFLAMMATORY CARDIOMYOPATHY
US 14.10.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 17225854 Applicant Eligo Bioscience Inventor Xavier Duportet

The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.

6.102020002248Trans-Vakzine: Impfstoffe gegen virale Erkrankungen, basierend auf einer Kombination eines Virusgenoms mit einem deletierten essentiellen Gen mit einer genetisch modifizierten Zelllinie, die das Produkt des Gens in trans zur Verfügung stellt, sowie Mittel und Verfahren zu ihrer Herstellung sowie ihre Anwendungen, insbesondere zur Herstellung eines Impfstoffs gegen Coronaviren.
DE 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 102020002248 Applicant Flaig Rüdiger Marcus Inventor Antrag auf Nichtnennung

Die Erfindung betrifft einen Impfstoff gegen virale Erkrankungen, basierend auf einer Kombination eines Virusgenoms mit einem deletierten essentiellen Gen mit einer genetisch modifizierten Zelllinie, die das Produkt des Gens in trans zur Verfügung stellt, sowie Mittel und Verfahren zu seiner Herstellung sowie seine Anwendungen, insbesondere zur Herstellung eines Impfstoffs gegen Coronaviren.

7.WO/2021/197212PHAGE DRUG-PROTEIN DISPLAY SYSTEM AND USE THEREOF
WO 07.10.2021
Int.Class C12N 15/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
Appl.No PCT/CN2021/083123 Applicant EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor YE, Bangce
Provided are a phage drug-protein display system and the use thereof. The phage drug-protein display system includes engineered bacteria and nucleic acid vectors, which can produce a phage displaying drug proteins. The phage drug-protein display system is used to construct a phage with an immune checkpoint blocking function according to requirements, enriching the methods for producing anti-tumor drugs and treating tumors.
8.WO/2021/200857BISPECIFIC ANTIBODY
WO 07.10.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2021/013378 Applicant MIE UNIVERSITY Inventor SHIKU Hiroshi
Provided are a novel antibody usable as an antitumor agent and an antitumor agent that comprises a molecule containing the antibody, etc. as an active ingredient. An antibody that contains heavy chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 54, heavy chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 55, heavy chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 56, light chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 57 or light chain CDRL1 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the seventh amino acid is W and/or the eighth amino acid is K, light chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 58, and light chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 59 or light chain CDRL3 comprising an amino acid sequence that is identical with the amino acid sequence represented by SEQ ID NO: 57 except that the second amino acid is A or S; or a binding fragment of the antibody.
9.WO/2021/197506RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD, RECOMBINANT PLASMID, AND USE THEREFOR
WO 07.10.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2021/095200 Applicant JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD Inventor XIAO, Wei
The present invention relates to a recombinant Newcastle disease virus and preparation method thereof, a recombinant plasmid, and a use for the recombinant Newcastle disease virus or the recombinant plasmid. The recombinant Newcastle disease virus is obtained by means of replacing the F protein of the LaSota strain of the Newcastle disease virus with the DNA encoded F protein shown at positions 7274-8935 from the 5' end of SEQ ID NO: 1. The recombinant Newcastle virus is capable of effectively inhibiting tumor cells and promoting apoptosis of tumor cells, and is safe.
10.20210309973Bacteriophage-Based Antibodies and Binders
US 07.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17222463 Applicant ATHANOR BIOSCIENCES, INC. Inventor HOSSEIN A. GHANBARI

Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides that include specific binding agents for proteinaceous targets at a surface of the capsid head. Therapeutic compositions, e.g., antiviral compositions, and methods of forming are described. A therapeutic composition can include an engineered bacteriophage that includes a polypeptide binds a pathogen or binds a cellular receptor of a pathogen at a surface of the bacteriophage. The engineered bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).